Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Hemostemix Inc. is a clinical-stage biotechnology company focused on the development and commercialization of autologous cell therapies for cardiovascular and vascular diseases. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on treatments for conditions involving inadequate blood flow and tissue ischemia. Hemostemix’s core technology centers on harnessing a patient’s own blood-derived cells to promote angiogenesis and tissue repair.
The company’s principal product candidate is ACP-01, an autologous cell therapy derived from a patient’s peripheral blood and processed to enrich angiogenic cell populations. ACP-01 is being developed primarily for critical limb ischemia and other ischemic cardiovascular indications. Hemostemix positions itself as a developer of personalized, minimally invasive therapies with potential advantages in safety and immune compatibility due to the autologous nature of its approach. The company was founded in 2003 in Canada and has evolved from early-stage cell biology research into a publicly traded clinical-stage company listed on the TSX Venture Exchange and the U.S. OTC Markets.
Business Operations
Hemostemix’s operations are centered on research, clinical development, and regulatory advancement of its cell therapy platform. The company operates as a single primary business segment focused on cell-based regenerative medicine, with revenue generation currently limited, as its lead therapy remains in the clinical development stage. Activities include clinical trials, manufacturing process development, intellectual property management, and engagement with regulatory authorities.
The company conducts its development activities primarily through internal research programs and contracted clinical and manufacturing partners. Hemostemix controls proprietary processes related to the isolation, expansion, and administration of angiogenic cell precursors used in ACP-01. As of publicly available disclosures, the company does not report material commercial revenues, and its operations are funded primarily through equity financing and strategic capital raises. Information regarding long-term commercial partnerships or revenue-generating subsidiaries is limited; data inconclusive based on available public sources.
Strategic Position & Investments
Hemostemix’s strategic direction is focused on advancing ACP-01 through later-stage clinical development and positioning the therapy for potential regulatory approval in key markets. Growth initiatives emphasize demonstrating clinical efficacy in ischemic indications, expanding intellectual property protection, and preparing scalable manufacturing processes suitable for commercialization.
The company has disclosed an interest in expanding the application of its angiogenic cell therapy platform to additional cardiovascular and ischemic conditions beyond its initial target indications. Public filings indicate that Hemostemix has not completed large-scale acquisitions and does not currently report a diversified portfolio of operating subsidiaries. Any material investments, licensing agreements, or late-stage strategic partnerships beyond its core development program are not clearly substantiated in public disclosures; data inconclusive based on available public sources.
Geographic Footprint
Hemostemix is headquartered in Canada, with its corporate offices and primary administrative functions based in Calgary, Alberta. Its operational footprint is concentrated in North America, where it conducts research, clinical trial coordination, and regulatory activities.
The company’s market focus includes Canada and the United States, reflecting the regulatory pathways and capital markets in which it operates. While Hemostemix has indicated an interest in global commercialization for its therapies, particularly in regions with high prevalence of cardiovascular disease, there is limited verified public information confirming active operations or investments outside North America. International expansion plans remain developmental based on available public disclosures.
Leadership & Governance
Hemostemix is led by an executive team with experience in biotechnology, clinical research, and corporate governance. The leadership’s stated strategic vision emphasizes advancing personalized regenerative therapies through disciplined clinical development and regulatory engagement, while maintaining shareholder alignment through capital stewardship.
Key executives and leaders include:
- Thomas Smeenk – Chief Executive Officer
- Dr. Fraser Henderson – Chief Scientific Officer
- Alicia Pankratz – Chief Financial Officer
- Robert B. McKee – Chairman of the Board
The board of directors provides oversight on clinical strategy, financing, and governance, with a focus on navigating the regulatory and capital requirements typical of early-stage biotechnology companies.